Profile data is unavailable for this security.
About the company
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
- Revenue in USD (TTM)0.00
- Net income in USD-191.62m
- Incorporated2009
- Employees108.00
- LocationKodiak Sciences Inc1200 PAGE MILL RDPALO ALTO 94304United StatesUSA
- Phone+1 (650) 281-0850
- Fax+1 (302) 636-5454
- Websitehttps://kodiak.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | 33.67m | -105.50m | 300.00m | 145.00 | -- | 1.24 | -- | 8.91 | -1.70 | -1.70 | 0.5217 | 3.44 | 0.095 | -- | 6.21 | 232,193.10 | -29.76 | -25.91 | -33.20 | -29.45 | -- | -- | -313.35 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Nautilus Biotechnology Inc | 0.00 | -70.21m | 301.35m | 161.00 | -- | 1.35 | -- | -- | -0.561 | -0.561 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -24.29 | -- | -25.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Neurogene Inc | 925.00k | -71.13m | 301.55m | 91.00 | -- | 1.92 | -- | 326.00 | -4.49 | -4.49 | 0.0582 | 10.56 | 0.0073 | -- | -- | 10,164.83 | -56.07 | -32.70 | -61.14 | -34.73 | -- | -- | -7,689.95 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -144.32m | 301.74m | 186.00 | -- | 1.56 | -- | -- | -2.19 | -2.19 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -52.83 | -40.85 | -57.18 | -44.48 | -- | -- | -- | -- | -- | -- | 0.1337 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| iTeos Therapeutics Inc | 35.00m | -121.25m | 303.86m | 157.00 | -- | 0.4811 | -- | 8.68 | -3.15 | -3.15 | 0.9064 | 17.29 | 0.05 | -- | 1.43 | 222,929.90 | -17.31 | 5.84 | -18.16 | 7.02 | -- | -- | -346.44 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Voyager Therapeutics Inc | 163.78m | 25.88m | 308.39m | 162.00 | 9.62 | 0.9338 | 9.97 | 1.88 | 0.5876 | 0.5876 | 2.94 | 6.06 | 0.4545 | -- | 14.29 | 1,011,012.00 | 7.18 | 0.6378 | 8.42 | 0.8203 | -- | -- | 15.80 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Lexicon Pharmaceuticals Inc | 5.23m | -216.39m | 312.11m | 285.00 | -- | 1.75 | -- | 59.69 | -0.7513 | -0.7513 | 0.018 | 0.4938 | 0.0175 | 0.6955 | 3.25 | 18,347.37 | -72.42 | -24.41 | -81.77 | -29.01 | 93.54 | 98.49 | -4,138.33 | -84.92 | 7.43 | -12.32 | 0.3588 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| SAGE Therapeutics Inc | 106.40m | -337.59m | 316.27m | 487.00 | -- | 0.5731 | -- | 2.97 | -5.58 | -5.58 | 1.76 | 9.02 | 0.1354 | -- | 5.24 | 218,478.40 | -42.95 | -21.88 | -48.97 | -23.30 | 91.75 | 99.63 | -317.29 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Design Therapeutics Inc | 0.00 | -47.78m | 318.21m | 54.00 | -- | 1.26 | -- | -- | -0.8465 | -0.8465 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -17.02 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -191.62m | 325.69m | 108.00 | -- | 1.76 | -- | -- | -3.65 | -3.65 | 0.00 | 3.52 | 0.00 | -- | -- | 0.00 | -41.64 | -31.73 | -46.43 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Silence Therapeutics plc | 22.43m | -50.25m | 327.09m | 115.00 | -- | 5.48 | -- | 14.58 | -0.4040 | -0.4040 | 0.1792 | 1.00 | 0.1273 | -- | 2.56 | 195,058.90 | -28.51 | -43.60 | -32.89 | -54.91 | 56.40 | -- | -224.01 | -287.30 | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| Jasper Therapeutics Inc | 0.00 | -63.53m | 330.78m | 45.00 | -- | 3.95 | -- | -- | -4.75 | -4.75 | 0.00 | 5.58 | 0.00 | -- | -- | 0.00 | -60.56 | -- | -68.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| AC Immune SA | 45.85m | -44.60m | 334.42m | 133.00 | -- | 2.30 | -- | 7.29 | -0.4571 | -0.4571 | 0.4744 | 1.47 | 0.2116 | -- | 3.19 | 344,710.40 | -20.59 | -18.25 | -29.04 | -19.52 | -- | -- | -97.29 | -148.29 | -- | -14.57 | 0.0231 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 339.58m | 33.00 | -- | 1.47 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
| AVITA Medical Inc | 60.04m | -57.32m | 349.74m | 207.00 | -- | 28.60 | -- | 5.83 | -2.23 | -2.23 | 2.33 | 0.4664 | 0.7409 | 1.53 | 7.30 | 290,048.30 | -70.74 | -- | -86.14 | -- | 86.46 | -- | -95.47 | -- | 3.37 | -11.27 | 0.7768 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Data as of Nov 25 2024. Currency figures normalised to Kodiak Sciences Inc's reporting currency: US Dollar USD
54.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Sep 2024 | 17.31m | 32.90% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.87m | 5.46% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 1.95m | 3.71% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.66m | 3.15% |
| ICONIQ Capital LLCas of 30 Sep 2024 | 1.02m | 1.93% |
| D. E. Shaw & Co. LPas of 30 Sep 2024 | 918.76k | 1.75% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 816.63k | 1.55% |
| Geode Capital Management LLCas of 30 Sep 2024 | 768.74k | 1.46% |
| Newtyn Management LLCas of 30 Sep 2024 | 740.51k | 1.41% |
| Stanford Management Co.as of 30 Sep 2024 | 691.77k | 1.32% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
